KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash from Operations (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Cash from Operations for 9 consecutive years, with 1158000000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 101.39% year-over-year to 1158000000.0, compared with a TTM value of 1649000000.0 through Dec 2025, up 32.24%, and an annual FY2025 reading of 1649000000.0, up 32.24% over the prior year.
  • Cash from Operations was 1158000000.0 for Q4 2025 at Teva Pharmaceutical Industries, up from 369000000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1184000000.0 in Q4 2023 and bottomed at 405000000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 332600000.0, with a median of 275500000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations crashed 232.79% in 2021, then skyrocketed 13760.0% in 2024.
  • Year by year, Cash from Operations stood at 456000000.0 in 2021, then surged by 113.38% to 973000000.0 in 2022, then rose by 21.69% to 1184000000.0 in 2023, then plummeted by 51.44% to 575000000.0 in 2024, then surged by 101.39% to 1158000000.0 in 2025.
  • Business Quant data shows Cash from Operations for TEVA at 1158000000.0 in Q4 2025, 369000000.0 in Q3 2025, and 227000000.0 in Q2 2025.